Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Kura Oncology ( (KURA) ) has provided an update.
On June 27, 2025, Kura Oncology entered into a Co-Promotion and Medical Affairs Agreement with Kyowa Kirin to co-promote ziftomenib, a selective oral menin inhibitor, in the United States for treating acute myeloid leukemia and other hematologic malignancies. This agreement, based on a prior collaboration from November 2024, outlines shared responsibilities in promotion and medical affairs, including cost-sharing and strategy development. The agreement remains effective until mutual termination or expiration of patent rights, regulatory exclusivity, or ten years after the first commercial sale.
The most recent analyst rating on (KURA) stock is a Buy with a $32.00 price target. To see the full list of analyst forecasts on Kura Oncology stock, see the KURA Stock Forecast page.
Spark’s Take on KURA Stock
According to Spark, TipRanks’ AI Analyst, KURA is a Neutral.
Kura Oncology faces challenges typical of biotech firms in transition, with positive revenue growth yet struggling profitability. Significant milestones in drug applications and a strong cash position are positive, but technical indicators and valuation metrics present caution. The company’s stock performance reflects these mixed factors.
To see Spark’s full report on KURA stock, click here.
More about Kura Oncology
Kura Oncology, Inc. operates in the biotechnology industry, focusing on developing innovative therapies for cancer treatment. The company specializes in creating targeted therapies, with a particular emphasis on hematologic malignancies such as acute myeloid leukemia.
Average Trading Volume: 1,363,887
Technical Sentiment Signal: Sell
Current Market Cap: $490.9M
For detailed information about KURA stock, go to TipRanks’ Stock Analysis page.